Database : MEDLINE
Search on : Malignant and Carcinoid and Syndrome [Words]
References found : 1772 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 178 go to page                         

  1 / 1772 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29424302
[Au] Autor:Corvino A; Fiorino F; Severino B; Saccone I; Frecentese F; Perissutti E; Di Vaio P; Santagada V; Caliendo G; Magli E
[Ad] Address:Dipartimento di Farmacia, Universita degli Studi di Napoli Federico II - Via D. Montesano, 49 - 80131, Napoli. Italy.
[Ti] Title:The Role of 5-HT1A Receptor in the Cancer as a New Opportunity in Medicinal Chemistry.
[So] Source:Curr Med Chem;, 2018 Feb 09.
[Is] ISSN:1875-533X
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:The 5-HT1A receptor is a pharmacologically well characterized serotonin receptor subtype and it has long been investigated because of its involvement in several physio-pathological mechanisms and treatment of neurological diseases like ansia and depression. Serotonin (5-HT) also shows many non-neural functions such as essential hypertension, embryogenesis, follicle maturation and behavior. Moreover it exerts a growth factor function on different types of non-tumoral cells, and it was also found to be related to oncogenes. In fact, growth-stimulatory activity of serotonin in different human tumor cells has been reported. Recently, new chemical molecules binding the 5-HT1A receptor have been described as novel therapeutic entities useful in neuroprotection, cognitive impairment, Parkinson's Disease, pain treatment, malignant carcinoid syndrome and cancer. It was widely demonstrated that 5-HT1A receptor is involved in the carcinogenesis and consequently in many human tumor types, such as prostate, bladder, small cell lung, colonrectal and cholangiocarcinoma. Furthermore depending on the tumor type, 5-HT1A receptor antagonists were shown to be able to block the 5HT-induced increase in tumor growth. In this review we have focused our attention on each tumor type where the 5-HT1A receptor is involved, investigating the role of this molecular target and the different classes of compounds that have shown the capability to modulate it. The analyzed aspects could represent the hint for the medical chemists to develop novel molecules as selective 5-HT1A agents useful to further elucidate the role this therapeutic target.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180209
[Lr] Last revision date:180209
[St] Status:Publisher
[do] DOI:10.2174/0929867325666180209141650

  2 / 1772 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28982960
[Au] Autor:Huguet I; Grossman A
[Ad] Address:Department of EndocrinologyHospital de la Princesa, Madrid, Spain ihm.huguet@gmail.com.
[Ti] Title:MANAGEMENT OF ENDOCRINE DISEASE: Flushing: current concepts.
[So] Source:Eur J Endocrinol;177(5):R219-R229, 2017 Nov.
[Is] ISSN:1479-683X
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVE: Flushing can be defined as a sensation of warmth accompanied by erythema that most commonly is seen on the face and which occurs in episodic attacks. Such a problem can be clinically problematic, since many conditions and drugs can be related to flushing, and while often there appears to be no underlying organic disease, it is important to exclude disorders since they may be life-threatening conditions. DESIGN AND METHODS: We performed a search in MEDLINE using the terms 'flushing' in combination with 'carcinoid syndrome', 'pheochromocytoma', 'mastocytosis', 'menopausal hot flush' and 'treatment'. European and American guidelines relating to neuroendocrine tumours, mastocytosis and menopause were reviewed. RESULTS: In this review, we discuss the main causes of flushing and propose an algorithm based on pathogenesis, which can be used to guide the clinical evaluation process. We also review recent significant developments in the assessment and treatment of the carcinoid syndrome and menopausal hot flushes, which should guide the clinical practice regarding this common but sometimes confusing condition. CONCLUSIONS: When evaluating flushing, a precise systematic approach is needed to exclude potentially serious underlying causes, although despite this, the cause of the disorder is not always found. If symptoms are not progressive, the patient should be advised about its apparently benign nature in order to avoid unnecessary studies or initiating treatments of minimal benefit.
[Mh] MeSH terms primary: Disease Management
Endocrine System Diseases/diagnosis
Endocrine System Diseases/therapy
Flushing/diagnosis
Flushing/therapy
[Mh] MeSH terms secundary: Adrenal Gland Neoplasms/diagnosis
Adrenal Gland Neoplasms/epidemiology
Adrenal Gland Neoplasms/therapy
Algorithms
Endocrine System Diseases/epidemiology
Flushing/epidemiology
Hot Flashes/diagnosis
Hot Flashes/epidemiology
Hot Flashes/therapy
Humans
Malignant Carcinoid Syndrome/diagnosis
Malignant Carcinoid Syndrome/epidemiology
Malignant Carcinoid Syndrome/therapy
Menopause/physiology
Neuroendocrine Tumors/diagnosis
Neuroendocrine Tumors/epidemiology
Neuroendocrine Tumors/therapy
Pheochromocytoma/diagnosis
Pheochromocytoma/epidemiology
Pheochromocytoma/therapy
Sweating/physiology
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1710
[Cu] Class update date: 171012
[Lr] Last revision date:171012
[Js] Journal subset:IM
[Da] Date of entry for processing:171007
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0295

  3 / 1772 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28807108
[Au] Autor:Sadeghian A; Rouhana H; Oswald-Stumpf B; Boh E
[Ad] Address:Department of Dermatology, Tulane University, New Orleans, Louisiana.
[Ti] Title:Etiologies and management of cutaneous flushing: Malignant causes.
[So] Source:J Am Acad Dermatol;77(3):405-414, 2017 Sep.
[Is] ISSN:1097-6787
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The second article in this 2-part continuing medical education series reviews the following malignant causes of flushing: mastocytosis, medullary thyroid carcinoma, pheochromocytoma, carcinoid tumors, gastroenteropancreatic neuroendocrine tumors, bronchogenic carcinoma, vasointestinal polypeptide secreting tumors, and renal cell carcinoma. The information provided will allow physicians to better distinguish patients who have worrisome presentations that require a more thorough investigation. Appropriate diagnostic workup and treatment options for these malignancies are reviewed.
[Mh] MeSH terms primary: Flushing/etiology
Neoplasms/complications
[Mh] MeSH terms secundary: Adrenal Gland Neoplasms/complications
Carcinoma, Neuroendocrine/complications
Carcinoma, Renal Cell/complications
Female
Humans
Kidney Neoplasms/complications
Male
Mastocytosis/complications
Pheochromocytoma/complications
Thyroid Neoplasms/complications
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1709
[Cu] Class update date: 170907
[Lr] Last revision date:170907
[Js] Journal subset:IM
[Da] Date of entry for processing:170816
[St] Status:MEDLINE

  4 / 1772 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28642733
[Au] Autor:Kim KJ; Yu JH; Kim NH; Kim YH; Kim YS; Seo JA
[Ad] Address:Division of Endocrinology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
[Ti] Title:A Case of Pulmonary Carcinoid Tumor with a Superimposed Aspergilloma Presenting As a Covert Ectopic Adrenocorticotropic Hormone Syndrome.
[So] Source:Front Endocrinol (Lausanne);8:123, 2017.
[Is] ISSN:1664-2392
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:Ectopic adrenocorticotropic hormone (ACTH) syndrome is a challenging diagnosis only responsible for approximately 10% of Cushing syndrome cases. It has been associated with a variety of benign and malignant tumors including a carcinoid tumor accompanied by aspergilloma in our case that was significantly difficult to be detected. We report a patient over 70 years old with uncontrolled hypertension and hypokalemia presenting with generalized edema. Laboratory results revealed ACTH-dependent Cushing syndrome, but imaging studies did not show any discrete lesions secreting ACTH. The petrosal to peripheral ACTH gradient resulted in no evidence of pituitary adenoma. As the only lesion suspicious for ectopic ACTH secretion was a right lower round cystic lesion that did not appear to be a carcinoid tumor on computed tomography scan of the chest, the patient underwent video-assisted thoracic surgical resection to provide a definitive diagnosis. The final diagnosis was a small ectopic ACTH-secreting carcinoid tumor with unusual superimposed aspergilloma in the periphery of the lung. Postoperatively, the abnormal endocrine levels were normalized, and all of the clinical symptoms and signs were ameliorated. This is an informative case of ectopic ACTH syndrome (EAS) that was the cause of hypokalemia, hypertension, metabolic alkalosis, and hypercortisolism despite its poorly specific cushingoid morphology and uncommon imaging findings. Therefore, we recommend that clinicians investigate any possible lesion as a potential source of EAS.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1706
[Cu] Class update date: 170816
[Lr] Last revision date:170816
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.3389/fendo.2017.00123

  5 / 1772 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28614007
[Au] Autor:Sathyakumar S; Paul TV; Asha HS; Gnanamuthu BR; Paul MJ; Abraham DT; Rajaratnam S; Thomas N
[Ti] Title:ECTOPIC CUSHING SYNDROME: A 10-YEAR EXPERIENCE FROM A TERTIARY CARE CENTER IN SOUTHERN INDIA.
[So] Source:Endocr Pract;23(8):907-914, 2017 Aug.
[Is] ISSN:1530-891X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVE: Ectopic adrenocorticotropic hormone (ACTH) secretion is a less common cause of Cushing syndrome and is seen in 5 to 10% of cases with endogenous hypercortisolemia. We hereby describe our experience of patients with ectopic ACTH syndrome, who have been managed over the past 10 years at a tertiary care center in Southern India. METHODS: The inpatient and outpatient records of patients from 2006 to 2015 were retrospectively reviewed. The clinical features, clinical history, biochemical values, imaging features, including radiologic findings and positron emission tomography scans, management, details of follow-up, and outcomes, were documented. We compared the biochemical findings in these patients with 20 consecutive patients with Cushing disease (Cushing syndrome of pituitary origin). RESULTS: A total of 21 patients were studied. The median age at presentation was 34 years (range, 19 to 55 years). Seven patients had thymic carcinoid, 7 had bronchial carcinoid, 3 had lung malignancies, 2 had medullary carcinoma thyroid, 1 patient had a pancreatic neuroendocrine tumor, and 1 patient had an occult source of ACTH. The most common clinical features at presentation were muscle weakness (95%), hyperpigmentation (90%), facial puffiness (76%), easy bruising (61%), edema (57%), and striae (52%). Extensive acne was seen in a large number of patients (43%). Only 3 patients (14%) had central obesity. The median 8 am cortisol was 55.5 µg/dL (range, 3.8 to 131 µg/dL), median 8 am ACTH was 207 pg/mL (range, 31.1 to 703 pg/mL), and the median 24-hour urinary free cortisol was 2,484 µg (range, 248 to 25,438 µg). Basal cortisol and ACTH, as well as midnight cortisol and ACTH level, were markedly higher in patients with ectopic Cushing syndrome as compared to patients with Cushing disease. Twelve of 21 patients had developed life-threatening infections by follow-up. Nine patients had undergone surgical intervention to address the primary tumor. However, only 1 patient exhibited a complete cure on follow-up. CONCLUSION: In our series, ectopic Cushing syndrome was most commonly seen in association with intrathoracic tumors such as bronchial or thymic carcinoid. Hyperpigmentation and proximal myopathy were frequent, while central obesity was uncommon. Early and rapid control of hypercortisolemia was important in order to prevent life-threatening infections and metabolic complications. ABBREVIATIONS: ACTH = adrenocorticotropic hormone CT = computed tomography DOTATATE = Ga-DOTA-Tyr -octreotate ECS = ectopic Cushing syndrome FDG = fluorodeoxyglucose MTC = medullary thyroid cancer NET = neuroendocrine tumor PET = positron emission tomography.
[Mh] MeSH terms primary: ACTH Syndrome, Ectopic/physiopathology
Cushing Syndrome/physiopathology
Neoplasms/secretion
[Mh] MeSH terms secundary: ACTH Syndrome, Ectopic/complications
ACTH Syndrome, Ectopic/diagnostic imaging
ACTH Syndrome, Ectopic/metabolism
Acne Vulgaris/etiology
Adult
Bronchial Neoplasms/diagnostic imaging
Bronchial Neoplasms/secretion
Carcinoid Tumor/diagnostic imaging
Carcinoid Tumor/secretion
Carcinoma, Neuroendocrine/diagnostic imaging
Carcinoma, Neuroendocrine/secretion
Cushing Syndrome/etiology
Cushing Syndrome/metabolism
Edema/epidemiology
Female
Humans
Hydrocortisone/metabolism
Hyperpigmentation/etiology
India
Lung Neoplasms/diagnostic imaging
Lung Neoplasms/secretion
Male
Middle Aged
Muscle Weakness/etiology
Neoplasms/diagnostic imaging
Neuroendocrine Tumors/diagnostic imaging
Neuroendocrine Tumors/secretion
Obesity, Abdominal/etiology
Organometallic Compounds
Pancreatic Neoplasms/diagnostic imaging
Pancreatic Neoplasms/secretion
Positron-Emission Tomography
Radiopharmaceuticals
Retrospective Studies
Tertiary Care Centers
Thymus Neoplasms/diagnostic imaging
Thymus Neoplasms/secretion
Thyroid Neoplasms/diagnostic imaging
Thyroid Neoplasms/secretion
Young Adult
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Organometallic Compounds); 0 (Radiopharmaceuticals); 9L17Y0H71P (dotatate gallium ga-68); WI4X0X7BPJ (Hydrocortisone)
[Em] Entry month:1710
[Cu] Class update date: 171012
[Lr] Last revision date:171012
[Js] Journal subset:IM
[Da] Date of entry for processing:170615
[St] Status:MEDLINE
[do] DOI:10.4158/EP161677.OR

  6 / 1772 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28612626
[Au] Autor:Colombo F; Janous P; Buxton N
[Ad] Address:a Department of Neurosurgery , The Walton Centre for Neurology and Neurosurgery , Liverpool , UK.
[Ti] Title:Carcinoid transformation of presacral dermoid cyst in patient with currarino syndrome: a case report.
[So] Source:Br J Neurosurg;:1-2, 2017 Jun 14.
[Is] ISSN:1360-046X
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Currarino syndrome (CS) is a congenital disorder characterized by partial sacral agenesis, anorectal malformation and a presacral mass. Only three cases of carcinoid transformation of the presacral mass have been described in the literature. We present a case of carcinoid transformation of presacral dermoid cyst in patient with Currarino syndrome.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1706
[Cu] Class update date: 170622
[Lr] Last revision date:170622
[St] Status:Publisher
[do] DOI:10.1080/02688697.2017.1339226

  7 / 1772 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28558450
[Au] Autor:Li WY; Huo H; Yang DH; Liu JH; Wang J; Jin XF; Niu YY
[Ad] Address:Department of Otorhinolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
[Ti] Title:[Transoral coblation-assisted endoscopic minimally invasive surgery for superficial tongue base tumours].
[So] Source:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi;52(5):332-336, 2017 May 07.
[Is] ISSN:1673-0860
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:To introduce the method of transoral coblation-assisted endoscopic minimally invasive surgery for superficial tongue base tumour. A total of 15 patients treated with transoral coblation-assisted endoscopic minimally invasive surgery from Mar. 2006 to Aug. 2016 were retrospectively reviewed. There were 9 patients with malignant tumors, 6 patients with benign neoplasms. Adjuvant postoperative radiation therapy was applied in three cases of squamous cell carcinoma, neck was performed in four cases of cancer. One case of non-Hodgkin lymphoma received postoperative chemotherapy. One case with ectopic thyroid gland was treated by subtotal resection and one case with squamous cell carcinoma changed into open surgery because of major lingual artery bleeding. The resection under edoscope was achieved in 92.86%(13/14)of patients. Fifteen cases of neoplasms were followed-up for 8-50 months(median 20 months), one patient with Cowden syndrome was lost to follow-up because of appendical carcinoid combined pulmonary metastasis, one patient with non-Hodgkin lymphoma died of recurrence in other head neck areas 2 years after chemotherapy. Transoral coblation-assisted endoscopic surgery can successfully treat for the patients with superficial tongue base tumours.
[Mh] MeSH terms primary: Carcinoma, Squamous Cell/surgery
Laryngeal Neoplasms/surgery
Natural Orifice Endoscopic Surgery/methods
Tongue Neoplasms/surgery
[Mh] MeSH terms secundary: Carcinoma, Squamous Cell/pathology
Carcinoma, Squamous Cell/radiotherapy
Female
Humans
Laryngeal Neoplasms/pathology
Laryngeal Neoplasms/radiotherapy
Lost to Follow-Up
Lymphoma, Non-Hodgkin/radiotherapy
Male
Minimally Invasive Surgical Procedures
Mouth
Neoplasm Recurrence, Local
Radiotherapy, Adjuvant
Retrospective Studies
Tongue Neoplasms/pathology
Tongue Neoplasms/radiotherapy
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1708
[Cu] Class update date: 170823
[Lr] Last revision date:170823
[Js] Journal subset:IM
[Da] Date of entry for processing:170601
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1673-0860.2017.05.003

  8 / 1772 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28526153
[Au] Autor:Borna RM; Jahr JS; Kmiecik S; Mancuso KF; Kaye AD
[Ad] Address:Department of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine at UCLA, Ronald Reagan UCLA Medical Center, 757 Westwood Plaza, Suite 3325, Los Angeles, CA 90095-7403, USA. Electronic address: rborna@mednet.ucla.edu.
[Ti] Title:Pharmacology of Octreotide: Clinical Implications for Anesthesiologists and Associated Risks.
[So] Source:Anesthesiol Clin;35(2):327-339, 2017 Jun.
[Is] ISSN:1932-2275
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Many patients presenting with a history of foregut, midgut neuroendocrine tumors (NETs) or carcinoid syndrome can experience life-threatening carcinoid crises during anesthesia or surgery. Clinicians should understand the pharmacology of octreotide and appreciate the use of continuous infusions of high-dose octreotide, which can minimize intraoperative carcinoid crises. We administer a prophylactic 500-µg bolus of octreotide intravenously (IV) and begin a continuous infusion of 500 µg/h for all NET patients. Advantages include low cost and excellent safety profile. High-dose octreotide for midgut and foregut NETs requires an appreciation of the pathophysiology involved in the disease, pharmacology, drug-drug interactions, and side effects.
[Mh] MeSH terms primary: Anesthesia
Anesthesiologists
Gastrointestinal Agents/pharmacology
Intraoperative Complications/prevention & control
Malignant Carcinoid Syndrome/prevention & control
Octreotide/pharmacology
[Mh] MeSH terms secundary: Carcinoid Tumor/chemistry
Carcinoid Tumor/drug therapy
Carcinoid Tumor/metabolism
Gastrointestinal Agents/administration & dosage
Gastrointestinal Agents/adverse effects
Gastrointestinal Agents/pharmacokinetics
Humans
Neuroendocrine Tumors/chemistry
Neuroendocrine Tumors/drug therapy
Neuroendocrine Tumors/metabolism
Octreotide/administration & dosage
Octreotide/adverse effects
Octreotide/pharmacokinetics
Risk
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Gastrointestinal Agents); RWM8CCW8GP (Octreotide)
[Em] Entry month:1711
[Cu] Class update date: 171106
[Lr] Last revision date:171106
[Js] Journal subset:IM
[Da] Date of entry for processing:170521
[St] Status:MEDLINE

  9 / 1772 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28507564
[Au] Autor:Gut P; Waligórska-Stachura J; Czarnywojtek A; Sawicka-Gutaj N; Baczyk M; Ziemnicka K; Fischbach J; Wolinski K; Kaznowski J; Wrotkowska E; Ruchala M
[Ad] Address:Department of Endocrinology, Poznan University of Medical Sciences, Poznan, Poland.
[Ti] Title:Management of the hormonal syndrome of neuroendocrine tumors.
[So] Source:Arch Med Sci;13(3):515-524, 2017 Apr 01.
[Is] ISSN:1734-1922
[Cp] Country of publication:Poland
[La] Language:eng
[Ab] Abstract:Gastroenteropancreatic neuroendocrine tumors (GEP/NET) are unusual and rare neoplasms that present many clinical challenges. They characteristically synthesize store and secrete a variety of peptides and neuroamines which can lead to the development of distinct clinical syndrome, however many are clinically silent until late presentation with mass effects. Management strategies include surgery cure and cytoreduction with the use of somatostatin analogues. Somatostatin have a broad range of biological actions that include inhibition of exocrine and endocrine secretions, gut motility, cell proliferation, cell survival and angiogenesis. Five somatostatin receptors (SSTR1-SSTR5) have been cloned and characterized. Somatostatin analogues include octreotide and lanreotide are effective medical tools in the treatment and present selectivity for SSTR2 and SSTR5. During treatment is seen disapperance of flushing, normalization of bowel movements and reduction of serotonin and 5-hydroxyindole acetic acid (5-HIAA) secretion. Telotristat represents a novel approach by specifically inhibiting serotonin synthesis and as such, is a promising potential new treatment for patients with carcinoid syndrome. To pancreatic functionig neuroendocrine tumors belongs insulinoma, gastrinoma, glucagonoma and VIP-oma. Medical management in patients with insulinoma include diazoxide which suppresses insulin release. Also mTOR inhibitors may inhibit insulin secretion. Treatment of gastrinoma include both proton pump inhibitors (PPIs) and histamine H2 - receptor antagonists. In patients with glucagonomas hyperglycaemia can be controlled using insulin and oral blood glucose lowering drugs. In malignant glucagonomas smatostatin analogues are effective in controlling necrolytic migratory erythemia. Severe cases of the VIP-oma syndrome require supplementation of fluid losses. Octreotide reduce tumoral VIP secretion and control secretory diarrhoea.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1705
[Cu] Class update date: 170518
[Lr] Last revision date:170518
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.5114/aoms.2016.60311

  10 / 1772 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 28477260
[Au] Autor:Soltysiak J; Ostalska-Nowicka D; Zaorska K; Sterzynska K; Derwich K; Zachwieja J
[Ad] Address:Department of Pediatric Cardiology, Nephrology and Hypertension, Poznan University of Medical Sciences, 27/33 Szpitalna Str, 60-572, Poznan, Poland. jsoltysiak1@gmail.com.
[Ti] Title:Atypical thymic carcinoid manifesting with nephrotic-range proteinuria in a 7-year-old boy.
[So] Source:Pediatr Nephrol;32(8):1465-1468, 2017 Aug.
[Is] ISSN:1432-198X
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:BACKGROUND: Nephrotic-range proteinuria as a paraneoplastic syndrome (PNS) is an exceptional presentation, especially in children. It is usually associated with hematologic malignancies. Solid tumors are very rare causes of proteinuria. CASE-DIAGNOSIS/TREATMENT: We present the case of a 7-year-old boy with an extremely rare atypical thymic carcinoid accompanied by nephrotic-range proteinuria as PNS. The kidney biopsy was consistent with minimal change disease (MCD). Tests for a neuroendocrine tumor were performed due to symptoms of hypercortisolemia and an elevated concentration of chromogranin A in the serum. The chest computed tomography revealed a tumor in the anterior mediastinum, which was diagnosed as an atypical thymic carcinoid. A complete resolution of the nephrotic-range proteinuria was observed within 1 week after the first thoracoscopic surgery, with almost complete reduction of the tumor mass. CONCLUSIONS: This extremely rare case shows that MCD can occur as a PNS even in children. Nephrotic-range proteinuria can be a symptom of malignant solid tumor. This case highlights the possibility of secondary causes of MCD in children.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1705
[Cu] Class update date: 171010
[Lr] Last revision date:171010
[St] Status:In-Process
[do] DOI:10.1007/s00467-017-3685-5


page 1 of 178 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information